Empagliflozin shows higher time in range in cystic fibrosis diabetes trial

ClinicalTrials.gov posted results on 21 September 2026 for a trial of empagliflozin in cystic fibrosis-related diabetes. Among 8 participants, mean continuous glucose monitor time in the 70–180 mg/dL range was 85% with empagliflozin and 78% with placebo.

Background

The study evaluated empagliflozin in overweight or obese patients with cystic fibrosis-related diabetes (CFRD), with cystic fibrosis also listed as a condition. Its stated aim was to collect pilot data on the safety, tolerability, and feasibility of treatment to support a future, larger randomized trial. The supplied record does not describe the drug’s mechanism, prior approvals, or the prevalence of CFRD.

Trial design

This Phase 2/Phase 3 study, registered as NCT06149793, enrolled 8 participants and was listed as active, not recruiting. It used a randomized, double-blind, placebo-controlled crossover design with a 4-week washout period. The intervention was empagliflozin. The registry record lists no primary-outcome entries.

Key results

Mean time in the continuous glucose monitor target range of 70–180 mg/dL was 85% (SD 9.7) with empagliflozin and 78% (SD 13.3) with placebo. Median area under the glucose curve was 397 mg*min/dL (SD 51) with empagliflozin and 417 mg*min/dL (SD 65) with placebo. Mean peak glucose was 241 mg/dL (SD 44) and 259 mg/dL (SD 54), respectively. No p-values, confidence intervals, or outcome analyses were supplied, and the record provided no adverse-event summary.

What this means

The posted measurements were numerically higher for time in range and lower for glucose area under the curve and peak glucose with empagliflozin than with placebo. Because the study enrolled only 8 participants and the registry supplied no statistical comparisons or adverse-event summary, these results do not establish treatment benefit or safety. The study’s stated purpose was to inform planning for a larger randomized trial.

Source

Source: ClinicalTrials.gov, registry results for “SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes,” posted 21 September 2026. Available at clinicaltrials.gov/study/NCT06149793.